Inhalation Research Services signs new order worth 74 000 EUR with leading Swiss generics company
(Stockholm, 18 March 2022) Inhalation Research Services (IRS) has signed a contract worth 74 000 Euros for a research project with a leading developer of inhaled generics. The project will compare in vitro data from ISAB’s dissolution module DissolvIt® with in vivo data from healthy volunteers, producing more milestone evidence of DissolvIt’s ability to produce predictive IVIVC (In Vitro-In Vivo Correlated) data. In January 2022 ISAB submitted a White Paper to the FDA aiming to validate DissolvIt® to become a recommended dissolution method for inhaled drug tests.IRS, the Contract Research